14 December 2011 - CureDuchenne, a US nonprofit organisation that finances research aimed at treating and curing Duchenne muscular dystrophy, said on Tuesday it had appointed senior pharmaceutical executive Michael G Kelly as its chief scientific officer.

Kelly, who has over 25 years of tra...

 

 

 

You must be logged in to view the whole article.
Click here if you require signing up